A Pandemic: 4 in every 10 cats will succumb to a fatal viral disease in their lifetime

If the World Health Organization considers that 0.4% of the human population infected with Covid-19 is a pandemic, then the following viral diseases in cats are true pandemics:

  1. It is estimated that 20% of 200 million owned cats around the world has either Feline Leukemia (FeLV), Feline Immunodeficiency Syndrome (FIV) or both;
  2. It is estimated that another 20% of 200 million owned cats around the world has Feline Infectious Peritonitis (FIP).

This means that 4 in every 10 cats will succumb to one of these fatal diseases in their lifetime. This high prevalence does not include the resurgence of an “old” disease, Feline Panleukopenia (FPV), and an emerging disease, Feline Herpesvirus type-1 (FHV-1).

In dogs, viral diseases are, fortunately, better controlled because of effective vaccines and vaccination programs. Unfortunately, we are seeing a resurgence in canine parvovirosis (CPV-2) and a new strain of canine distemper (CDV), especially in breeding farms and kennels.

Check out on the Communities page to read the experiences of NEW cat owners about RetroMAD1


“In over 100 cases of cats suffering from feline leukemia, presented by their owners from Germany, Malaysia, Singapore, South Africa, and the U.S. that received RetroMAD1TM treatment, the lives of all these cats improved so dramatically that owners could not believe what they witnessed. Without a doubt, RetroMAD1TM saves lives.”

- Dr Cher Yew NG, CEO of Biovalence


RetroMAD1TM - The future of anti-viral treatment

With more than 10 years of research and development using a patented recombinant proteomic technology, RetroMAD1TM is the most advanced and true antiviral molecule that demonstrates excellent therapeutic value specifically targeting fatal viral diseases in cats and dogs namely FeLV, FIV, FIP, CPV2, and CDV. With its wide therapeutic index and ease of oral application, RetroMAD1TM is positioned as a drug of the first choice for veterinarians and pet owners in antiviral therapy and immune-modulator prophylaxis. RetroMAD1TM is further envisaged for use in individual pets and pets living in high-risk communities to aid in the prevention of the spread of these fatal diseases.


A broad-spectrum antiviral against medically important/fatal diseases of dogs and cats, RetroMAD1TM is

1.  An aqueous liquid for oral use, allowing patient and pet owner compliance;

2.  Safe up to 300mg per kg of body weight;

3.  Designed for community use* like in a shelter, breeding cattery or kennel.

* Similar to Pre-exposure prophylaxis (or PrEP) when people at very high risk from HIV infection take HIV medicine daily to lower their chances of getting infected